Kidney Transplant

  • Kidney Transplant Home
  • AlloSure
  • KidneyCare

AlloSure is the first and only clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury. AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.

The most comprehensive tool for transplant patient surveillance. KidneyCare combines clinically validated AlloSure test with research use only AlloMap Kidney and iBox, enabling you to follow trends and trajectory of kidney allograft health.

Request Information

Subscribe

* indicates required
I am a

Drive better outcomes for Kidney transplant recipients

Better Surveillance. Better Outcomes.

AlloSure is the first non-invasive test that assesses organ health by directly measuring allograft injury, enabling better management of your kidney transplant recipients.

What is AlloSure?

AlloSure is a clinically and analytically validated, non-invasive donor-derived cell-free DNA (dd-cfDNA) test for identifying kidney injury.

  • The first and only transplant dd-cfDNA developed specifically for transplant recipients
  • Validated in prospective multicenter study
  • A non-invasive blood test that does not require prior genotyping of the donor or recipient
  • A rejection rule-out test that has high specificity

WHAT IS CELL-FREE DNA (cfDNA)?

  • Cell-free DNA refers to fragments of DNA in the bloodstream that originate from cells undergoing cell injury and death
  • DNA degrades into nucleosomal units consisting of ~166 bases
  • Cell-free DNA is cleared from the blood by the liver and kidney and has a half-life of about 30 minutes

AlloSure is validated and reimbursable through Medicare

  • AlloSure is validated in a 14 center prospective study
  • Broadly used in over 115 transplant centers
  • May be used in re-transplants
  • AlloSure is covered by Medicare

Request Information

Subscribe

* indicates required
I am a

It’s time for innovation

THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE.

The most comprehensive tool for transplant patient surveillance.*

What is KidneyCare?

KidneyCare is the most comprehensive option for surveilling kidney allograft health, combining our clinically-validated AlloSure Kidney dd-cfDNA test, gene expression profiling with AlloMap Kidney, and predictive intelligence with iBox.

The Latest innovation in Kidney Transplant Surveillance can Drive Better Outcomes for your Patients.

Graft Injury

  • The first non-invasive dd-cfDNA blood test that measure allograft injury
  • Clinically validated through prospective, multicenter studies
  • Developed specifically for transplants recipients

Immune Quiescence

  • Gene Expression Profiling (GEP) to evaluate the level of immunoquiescence
  • Developed from 15 years of experience with AlloMap Heart
iBox_Logo_CMYK-01

Graft Survival Prognosis

  • An integrative and accurate risk prediction score for kidney allograft health
  • Prognostic indication of allograft survival at 3, 5 and 7 years
  • Six center, three country validation

Request Information

Subscribe

* indicates required
I am a

*KidneyCare is available for research use only and not intended for diagnostic procedures.